Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects

Published:2023-07 Issue: Volume:Volume 17 Page:2137-2145
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Jiang Xu^ORCID,Bae Sungyeun^ORCID,Yoon Deok Yong,Park Shin Jung,Oh Jaeseong^ORCID,Cho Joo-Youn^ORCID,Yu Kyung-Sang^ORCID

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference39 articles.

1. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045

2. Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data

3. Department, S.R. Number of deaths in South Korea in 2020, by cause of death; 2021. Available from: http://kostat.go.kr. Accessed July 17, 2023.

4. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

5. Development of SGLT1 and SGLT2 inhibitors

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects;Pharmaceuticals;2024-04-18

2. Bioequivalence assessment of two formulations of empagliflozin in healthy adult subjects;American Journal of Pharmacotherapy and Pharmaceutical Sciences;2023-11-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP